S&P 500   2,986.20 (-0.39%)
DOW   26,770.20 (-0.95%)
QQQ   191.69 (-0.96%)
AAPL   236.41 (+0.48%)
FB   185.85 (-2.38%)
MSFT   137.41 (-1.63%)
GOOGL   1,244.41 (-0.67%)
AMZN   1,757.51 (-1.68%)
CGC   20.21 (-2.65%)
NVDA   190.49 (-1.96%)
MU   43.47 (-4.46%)
BABA   169.13 (-4.37%)
GE   8.96 (-0.88%)
TSLA   256.95 (-1.92%)
AMD   30.97 (-0.55%)
T   38.47 (+1.75%)
F   9.29 (+1.98%)
ACB   3.68 (-5.40%)
PRI   123.53 (-0.44%)
NFLX   275.30 (-6.15%)
BAC   30.35 (+0.30%)
GILD   64.91 (-0.49%)
DIS   130.89 (-1.12%)
S&P 500   2,986.20 (-0.39%)
DOW   26,770.20 (-0.95%)
QQQ   191.69 (-0.96%)
AAPL   236.41 (+0.48%)
FB   185.85 (-2.38%)
MSFT   137.41 (-1.63%)
GOOGL   1,244.41 (-0.67%)
AMZN   1,757.51 (-1.68%)
CGC   20.21 (-2.65%)
NVDA   190.49 (-1.96%)
MU   43.47 (-4.46%)
BABA   169.13 (-4.37%)
GE   8.96 (-0.88%)
TSLA   256.95 (-1.92%)
AMD   30.97 (-0.55%)
T   38.47 (+1.75%)
F   9.29 (+1.98%)
ACB   3.68 (-5.40%)
PRI   123.53 (-0.44%)
NFLX   275.30 (-6.15%)
BAC   30.35 (+0.30%)
GILD   64.91 (-0.49%)
DIS   130.89 (-1.12%)
Log in

Repligen Stock Price, News & Analysis (NASDAQ:RGEN)

$78.48
-0.78 (-0.98 %)
(As of 10/18/2019 04:00 PM ET)
Today's Range
$77.51
Now: $78.48
$79.70
50-Day Range
$73.75
MA: $81.52
$94.32
52-Week Range
$48.26
Now: $78.48
$99.25
Volume228,294 shs
Average Volume506,788 shs
Market Capitalization$4.04 billion
P/E Ratio107.51
Dividend YieldN/A
Beta1.14
Repligen Corporation develops, manufactures, and sells products used to enhance the interconnected phases of the biological drug manufacturing process in North America, Europe, APAC, and internationally. It offers Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins; and growth factor products used to supplement cell culture media. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:RGEN
CUSIP75991610
Phone781-250-0111

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$194.03 million
Cash Flow$1.11 per share
Book Value$14.03 per share

Profitability

Net Income$16.62 million

Miscellaneous

Employees548
Market Cap$4.04 billion
Next Earnings Date11/7/2019 (Estimated)
OptionableOptionable

Receive RGEN News and Ratings via Email

Sign-up to receive the latest news and ratings for RGEN and its competitors with MarketBeat's FREE daily newsletter.


Repligen (NASDAQ:RGEN) Frequently Asked Questions

What is Repligen's stock symbol?

Repligen trades on the NASDAQ under the ticker symbol "RGEN."

How were Repligen's earnings last quarter?

Repligen Co. (NASDAQ:RGEN) announced its quarterly earnings results on Thursday, August, 1st. The biotechnology company reported $0.31 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $0.25 by $0.06. The biotechnology company earned $70.70 million during the quarter, compared to the consensus estimate of $65.47 million. Repligen had a return on equity of 6.92% and a net margin of 11.42%. Repligen's revenue for the quarter was up 48.1% on a year-over-year basis. During the same period in the previous year, the business earned $0.14 EPS. View Repligen's Earnings History.

When is Repligen's next earnings date?

Repligen is scheduled to release their next quarterly earnings announcement on Thursday, November 7th 2019. View Earnings Estimates for Repligen.

What guidance has Repligen issued on next quarter's earnings?

Repligen issued an update on its FY19 earnings guidance on Thursday, August, 1st. The company provided earnings per share (EPS) guidance of $0.94-0.98 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.96. The company issued revenue guidance of $264-268 million, compared to the consensus revenue estimate of $255.79 million.

What price target have analysts set for RGEN?

9 Wall Street analysts have issued 12-month target prices for Repligen's shares. Their forecasts range from $70.00 to $110.00. On average, they anticipate Repligen's share price to reach $100.71 in the next year. This suggests a possible upside of 28.3% from the stock's current price. View Analyst Price Targets for Repligen.

What is the consensus analysts' recommendation for Repligen?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Repligen in the last year. There are currently 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Repligen.

What are Wall Street analysts saying about Repligen stock?

Here are some recent quotes from research analysts about Repligen stock:
  • 1. HC Wainwright analysts commented, "We utilize a discounted cash flow (DCF)-driven analysis approach to value Repligen shares. Our assessment yields an enterprise value of roughly $5.5B. We utilize a roughly 7.5% discount rate (vs. the previous 9%) and 26% effective tax rate. This yields a market value of the firm of $5.7B, assuming roughly $527M in cash as of mid-2020, which reflects the proceeds from the $287.5M convertible note offering completed in July 2019. Given the projected 52M shares outstanding as of mid-2020, this yields a price objective of roughly $110 per share." (8/12/2019)
  • 2. According to Zacks Investment Research, "Repligen Corporation is a life sciences company focused on the development, production and commercialization of high-value consumable products used in the process of manufacturing biological drugs. Their bioprocessing products are sold to major life sciences and biopharmaceutical companies worldwide. They are a leading manufacturer of Protein A, a critical reagent used to separate and purify monoclonal antibody therapeutics. They also supply several growth factor products used to increase cell culture productivity during the fermentation stage of drug manufacturing. In addition, they have developed and marketed their OPUS® series of pre-packed plug-and-play chromatography columns, and they provide test kits to ensure final product quality. Aside from their core bioprocessing business, they have a portfolio of clinical-stage partnering assets, including a pancreatic imaging agent in Phase 3 development and an orphan drug candidate in Phase 1 development. " (8/7/2019)

Has Repligen been receiving favorable news coverage?

News coverage about RGEN stock has trended negative on Friday, according to InfoTrie. InfoTrie identifies negative and positive news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Repligen earned a news sentiment score of -2.0 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for Repligen.

Who are some of Repligen's key competitors?

What other stocks do shareholders of Repligen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Repligen investors own include Netflix (NFLX), Corcept Therapeutics (CORT), Alibaba Group (BABA), Micron Technology (MU), NVIDIA (Nvda), Okta (OKTA), salesforce.com (CRM), Twilio (TWLO), Trade Desk (TTD) and Xilinx (XLNX).

Who are Repligen's key executives?

Repligen's management team includes the folowing people:
  • Mr. Anthony J. Hunt, CEO, Pres, Director & Member of Scientific Advisory Board (Age 55)
  • Mr. Jon K. Snodgres, CFO & Sec. (Age 53)
  • Mr. Steve Curran, VP of Global Operations
  • Ms. Sondra S. Newman, Sr. Director of Investor Relations
  • Mr. Stephen Tingley, VP of Sales

Who are Repligen's major shareholders?

Repligen's stock is owned by a number of of retail and institutional investors. Top institutional investors include Stephens Investment Management Group LLC (1.40%), Copper Rock Capital Partners LLC (0.45%), Summit Creek Advisors LLC (0.16%), Stephens Inc. AR (0.11%), Envestnet Asset Management Inc. (0.04%) and Pacer Advisors Inc. (0.03%). Company insiders that own Repligen stock include Anthony Hunt, Glenn L Md Cooper, Howard Benjamin, Jon Snodgres, Karen A Dawes, Nicolas Barthelemy, Ralf Kuriyel, Roy T Eddleman and Thomas F Ryan Jr. View Institutional Ownership Trends for Repligen.

Which institutional investors are selling Repligen stock?

RGEN stock was sold by a variety of institutional investors in the last quarter, including Copper Rock Capital Partners LLC, Stephens Investment Management Group LLC, State of Alaska Department of Revenue, Summit Creek Advisors LLC and Envestnet Asset Management Inc.. Company insiders that have sold Repligen company stock in the last year include Anthony Hunt, Glenn L Md Cooper, Jon Snodgres, Karen A Dawes, Ralf Kuriyel and Thomas F Ryan Jr. View Insider Buying and Selling for Repligen.

Which institutional investors are buying Repligen stock?

RGEN stock was acquired by a variety of institutional investors in the last quarter, including Pacer Advisors Inc., Navellier & Associates Inc, Campbell & CO Investment Adviser LLC, Fox Run Management L.L.C., Stephens Inc. AR, Meeder Asset Management Inc., Zurcher Kantonalbank Zurich Cantonalbank and Redhawk Wealth Advisors Inc.. View Insider Buying and Selling for Repligen.

How do I buy shares of Repligen?

Shares of RGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Repligen's stock price today?

One share of RGEN stock can currently be purchased for approximately $78.48.

How big of a company is Repligen?

Repligen has a market capitalization of $4.04 billion and generates $194.03 million in revenue each year. The biotechnology company earns $16.62 million in net income (profit) each year or $0.73 on an earnings per share basis. Repligen employs 548 workers across the globe.View Additional Information About Repligen.

What is Repligen's official website?

The official website for Repligen is http://www.repligen.com/.

How can I contact Repligen?

Repligen's mailing address is 41 SEYON STREET BUILDING 1 SUITE 100, WALTHAM MA, 02453. The biotechnology company can be reached via phone at 781-250-0111 or via email at [email protected]


MarketBeat Community Rating for Repligen (NASDAQ RGEN)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  289 (Vote Outperform)
Underperform Votes:  274 (Vote Underperform)
Total Votes:  563
MarketBeat's community ratings are surveys of what our community members think about Repligen and other stocks. Vote "Outperform" if you believe RGEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RGEN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/18/2019 by MarketBeat.com Staff

Featured Article: Cost of Debt

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel